Cassava Sciences, Inc.

SAVA
NASDAQ
Last Updated: 9/28/2022 1:20:41 PM
Price
46.18
Changes
0.99
% Change
2.19
Volume
3488699
52 Week
High
100
52 Week
Low
13.84
About Cassava Sciences, Inc.
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Cassava Sciences, Inc. Company Details
CEO:   Mr. Remi Barbier
Country:   US
Industry:   Biotechnology
Website:   https://www.cassavasciences.com
Exchange:   NASDAQ Capital Market
IPO\Launch Date:   2000-07-14
Cassava Sciences, Inc. Company Executive Details
  Dr. James W. Kupiec M.D.
  Chief Clinical Devel. Officer
  Dr. Lindsay H. Burns Ph.D.
  Senior Vice President of Neuroscience
  Mr. Michael Zamloot
  Senior Vice President of Technical Operations
  Dr. George Thornton
  Senior Vice President of Technology
  Dr. Nadav Friedmann
  Chief Medical Officer & Director

Cassava Sciences, Inc. Latest News

5 Investors Betting Big on Cassava (SAVA) Stock


Shares of Cassava Sciences (NASDAQ: SAVA ) are down by over 15% following the previous day's gain of 35%. Yesterday, the Securities and Exchange Commission (SEC) announced that it had closed its case on Cassava.


Published on: 2022-09-23 14:14:27

Impact on Symbol / Company: SAVA

View News

Cassava: High Risk Speculative Play With Enormous Potential


Initiation of a phase 3 program open-label extension study using Simufilam for patients with Alzheimer's Disease is expected in 2nd half of 2022. An ongoing long-term open label study, initiated in March of 2020 is ongoing; Dosing completion is expected Q4 of 2022 and results from it are expected before end of 2022.


Published on: 2022-09-22 17:44:00

Impact on Symbol / Company: SAVA

View News

The Huge Reason Cassava Sciences (SAVA) Stock Is Rocketing Higher


Deleted: Despite a significant down day for the S&P 500, shares of Cassava Sciences (NASDAQ: SAVA ) closed higher by 35%. That's because the Securities and Exchange Commission (SEC) has closed its case on Cassava following the initiation of an investigation last November.


Published on: 2022-09-22 16:45:37

Impact on Symbol / Company: SAVA

View News

Cassava Skyrockets After SEC Clears It Of Tampering With Alzheimer's Data


The SEC reportedly cleared an investigation into Cassava Sciences, leading SAVA stock to hit a seven-month high Thursday. The post Cassava Skyrockets After SEC Clears It Of Tampering With Alzheimer's Data appeared first on Investor's Business Daily.


Published on: 2022-09-22 15:06:54

Impact on Symbol / Company: SAVA

View News

The SEC Has Officially Cleared Cassava Sciences


Cassava Sciences increased by over 10% intraday on positive SEC news. Cassava Sciences is up 26% in the last month while the market is down 7%.


Published on: 2022-09-22 08:00:00

Impact on Symbol / Company: SAVA

View News

What Is Going on With Cassava (SAVA) Stock Today?


Cassava Sciences (NASDAQ: SAVA ) stock rose nearly 30% on Sept. 20 as speculators bet on the company's efforts against Alzheimer's Disease.


Published on: 2022-09-21 09:36:01

Impact on Symbol / Company: SAVA

View News

Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference


AUSTIN, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it has been invited to present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference, being held in New York.


Published on: 2022-09-08 09:15:00

Impact on Symbol / Company: SAVA

View News

Cassava Sciences Looks As Good Of A Purchase As Ever


Multiple insiders have purchased shares on the open market in the last month. The company has now released positive 100 patient 12-month data.


Published on: 2022-09-03 01:24:12

Impact on Symbol / Company: SAVA

View News

Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock


Cassava Sciences (NASDAQ: SAVA ) rose 9% overnight on reports director Richard Barry has invested $860,000 in the company's stock. The stock was due to open Aug. 26 at almost $30 per share, a market capitalization of almost $1.2 billion.


Published on: 2022-08-26 10:14:55

Impact on Symbol / Company: SAVA

View News

These Are The Ten Best And Worst Performing Small-Cap Stocks In July 2022


The small-cap Russell 2000 gained over 10% in July, compared to a jump of 9.1% for the S&P 500.


Published on: 2022-08-22 20:08:00

Impact on Symbol / Company: SAVA

View News

Cassava Sciences, Blue Apron, and Revlon Stocks Exploded Out of the Gate Wednesday Morning


These vastly different companies have one thing in common.


Published on: 2022-08-17 13:40:00

Impact on Symbol / Company: SAVA

View News

Why Is Cassava Sciences (SAVA) Stock Up 20% Today?


Cassava Sciences (NASDAQ: SAVA ) rose 20% in overnight trading after board member Sanford Robertson bought 100,000 shares. Chief financial officer Eric Schoen also bought shares.


Published on: 2022-08-17 10:02:13

Impact on Symbol / Company: SAVA

View News

Grow your Money

We helps you in understanding the science behind growing the money, which will help you diversify your funds as per your requirements and helps in achieving your retirement goals, children education, investment in property, business or any smart looking startup ventures

Services we Offer

We offer several services including expert recommendations & suggestions on buying ETF, Mutual Funds, Bonds, Debt securities, Equities, Property invesments and several others

Live Market Data

We provide you live market data for your analysis, review and looking out for quick buying opportunities to help you